The Usefulness of Fecal Calprotectin in the era of the COVID-19 Pandemic
- 1 June 2021
- journal article
- letter
- Published by Elsevier BV in Gastroenterology
- Vol. 160 (7), 2623-2625
- https://doi.org/10.1053/j.gastro.2020.05.045
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and EndoscopyGastroenterology, 2020
- AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert CommentaryGastroenterology, 2020
- SARS-CoV-2 Gastrointestinal Infection Causing Hemorrhagic Colitis: Implications for Detection and Transmission of COVID-19 DiseaseAmerican Journal Of Gastroenterology, 2020
- ACG Clinical Guideline: Management of Crohn's Disease in AdultsAmerican Journal Of Gastroenterology, 2018
- Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years — United States, 2015Published by Centers for Disease Control MMWR Office ,2016
- Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohnʼs DiseaseInflammatory Bowel Diseases, 2016
- Monitoring inflammatory bowel disease activity: Clinical activity is judged to be more relevant than endoscopic severity or biomarkersJournal of Crohn's and Colitis, 2012
- Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's diseaseGut, 2005